In the near future，The overseas COVID-19 epidemic once again aroused widespread concern in the international community. According to the CDC data of the United States, the number of confirmed cases and hospitalization of COVID-19 in the United States continues to rise.，Not only that, Japan's Fuji Television reported a shocking news on May 12, 2022: "Six new cases of infection of COVID-19 mutant virus Omicron new recombinant strain in Tokyo, Japan". It is understood that this is the first time such a recombinant strain has been found in Tokyo, and the six patients have not even traveled overseas.
Figure 1: statistics on COVID-19 epidemic situation in the United States
Over the years,As one of the major sudden infectious diseases, COVID-19 constantly tests the prevention and control mechanisms and systems of infectious diseases all over the world, and also challenges innovative pharmaceutical companies that specialize in viral diseases.. According to China's Law on Prevention and treatment of Infectious Diseases, infectious diseases are divided into three categories: category A, Class B and Class C. among them, the National Health Commission brings the pneumonia infected by novel coronavirus into Class B management of legal infectious diseases and takes measures for the prevention and control of Class An infectious diseases.
In addition, China also starts from the top-level design to strengthen the ability of prevention and control of infectious diseases. On May 10, 2022, the National Development and Reform Commission issued China's first five-year plan for bio-economy, the 14th five-year Plan for Bio-economic Development. According toBai Jingyu, director of the Innovation-driven Development Center of the National Development and Reform Commission, said: "through five years of hard workStrive to achieve a total biological economy of 22 trillion yuan by 2025.Among them, the total amount of core industries exceeds 7.5 trillion yuan, thus making the biological economy a strong driving force for the high-quality development of China's economy. "
It is worth mentioning that the "Planning" policy has pointed out four key development areas, and in the field of biosafety, it is required to strengthen the research and development of drugs for the treatment of infectious diseases and improve the prevention and control mechanism of major emerging infectious diseases. The author believes that, on the whole, China's biological economy will be strongly supported by policies, andA new stage of development will also be ushered in in subdivided areas such as the prevention and control of infectious diseases.。
Figure 2: the Plan encourages the development of biosafety.
A classic case of innovative pharmaceutical companies, Golly Pharmaceuticals grasps the opportunity of the times.
If we consider this top-level design at the enterprise level, we can find that if innovative pharmaceutical companies continue to explore in the direction of policy support and encouragement, they will be guided by the policy "compass" and are more likely to embark on the correct growth path. in order to get greater opportunities for development.
The author notes that Goliath Pharmaceutical-B (1672.HK), which focuses on the development and commercialization of innovative drugs, is one of the most typical companies. Golly focuses its research on viral diseases, non-alcoholic fatty liver and tumors. The development and research of Goliath in the field of viral diseases corresponds to the prevention and control of infectious diseases mentioned in the policy.
In fact, Golly has profound attainments in the field of viral diseases, especially in some world-class major diseases.For example, Gurley's AIDS research product ASC22 (Envoli Monoclonal Antibody) has brought good news for mankind to overcome incurable diseases. Recently, the company announced that the application for phase I/II clinical trials of immune reconstitution / functional cure for HIV-1-infected people has been approved. The clinical progress of the product is smooth, which is one step closer to the successful product development and then approval to market.
In terms of viral hepatitis, Gurley's research product ASC22 (Envoli Monoclonal) was presented at the 2021 Beauty liver Society, and its breakthrough efficacy brings hope of functional cure for about 300 million patients with chronic hepatitis B worldwide. And Goliath's hepatitis C has been put on the market by Xinlilai®And Gonowei.®The complete oral direct anti-hepatitis C virus program was selected into the new health insurance catalogue in 2021. Thus it can be seen that Goliath's hepatitis B and C drugs will contribute to China's vision of "eliminating viral hepatitis by 2030" put forward by the World Health Organization (WHO).
Figure 3: the academic publication of Golly Pharmaceuticals
Not only that, Goliath is in the process of studying the treatment of AIDS, hepatitis B, hepatitis C and other emerging infectious diseases.It was found that ritonavir, which was originally used for the treatment of AIDS, could also be used as an enhancer in the treatment of COVID-19, and Golly also quickly commercialized it by taking a series of measures.In terms of production, Golly quickly responded to market demand and put forward a plan to expand production, with an annual production capacity of about 530 million tablets. In terms of commercialization, Golly reached a distribution agreement with a company owned by China Pharmaceutical, which has a strong sales ability and is also responsible for the commercial operation of COVID-19 's oral drug Paxlovid, produced by Pfizer Inc, in the Chinese mainland market.
Through Golly to seize the opportunity of ritonavir, an anti-COVID-19 drug, it is not difficult to find that Goliath has a keen commercial sense and strong execution.In addition, Gurley is also constantly expanding its product line of viral diseases, and is currently developing ASC10 and ASC11, two oral small molecule therapeutic drugs for COVID-19, and on April 19, 2022, Gurley announced that 3CLpro inhibitor ASC11 is expected to become an effective drug for the treatment of COVID-19, which may play an important role in the prevention and treatment of the global COVID-19 epidemic in the future.
Figure 4: Goliath Pharmaceutical's viral disease product line
Summary
The author believes that policies and enterprises complement each other. Golly has a strong vision of its own strength, and the selected industry areas are supported by policies. At the same time, Gurley's outstanding contribution in the field of infectious diseases has also helped the country to achieve its policy goals more satisfactorily. Goliath's subcutaneous injection of PD-L1 monoclonal antibody ASC22 as a macromolecular biological drug will also provide a better treatment for the functional cure of AIDS and hepatitis B and promote the development of biological economy in China.
Recently, Golly Pharmaceuticals获IncludeMSCI China small cap index（Effective after the market closes on May 31, 2022），It fully reflects the high recognition of the company's R & D strength and innovation potential by the international capital market. The international popularity of Golly will be enhanced and more capital inflows are expected, thereby improving the liquidity of the company's stock trading. Looking to the future, Golly will continue to comply with the trend of industry development and policy guidance, develop more innovative drugs for patients, better meet the needs of the market and achieve win-win results, which is worthy of long-term attention.